(Q46740615)

24 December 2017

title

BIRB-796 is not an effective ABL(T315I) inhibitor (English)

1 reference

24 December 2017

author

Brian Druker

series ordinal

2

1 reference

24 December 2017

author name string

Thomas O'Hare

series ordinal

1

1 reference

24 December 2017

publication date

1 October 2005

1 reference

24 December 2017

published in

Nature Biotechnology

1 reference

24 December 2017

volume

23

1 reference

24 December 2017

issue

10

1 reference

24 December 2017

page(s)

1209-10; author reply 1210-1

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1038/nbt1005-1209

exact match

0 references

cites work

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1005-1209

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1005-1209

AMN107: tightening the grip of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1005-1209

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1005-1209

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1005-1209

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1005-1209

21 January 2018

Identifiers

DOI

10.1038/NBT1005-1209

1 reference

24 December 2017

PubMed ID

16211050

1 reference

24 December 2017